Better treatment for breast cancer relapses

Thanks to Lymphodivpenia, a biomarker developed by Grenoble-based ImmunID, doctors can offer more targeted treatment to metastatic breast cancer patients suffering from a relapse. This is the main conclusion of research published in Oncoimmunology in July 2012, and confirms the findings of two previous studies. A total of 133 patients have been tracked so far.
Lymphodivpenia lets doctors estimate the three-year survival probability of cancer patients and determine the best treatment option, either conventional chemotherapy or chemotherapy following treatment to strengthen the patient’s immune system, and the best clinical care. These findings—a first for metastatic cancer—are currently being confirmed on a larger patient sample.

Contact: npasqual@immunid.com

Facebook

Twitter